Exact Sciences Corp (EXAS)
52.91
-0.16
(-0.30%)
USD |
NASDAQ |
Nov 22, 16:00
52.87
-0.04
(-0.08%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 9.792B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -19.07% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 3.599 |
Price to Book Value | 3.050 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.80 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 80.42% |
Profile
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
URL | https://www.exactsciences.com |
Investor Relations URL | https://investor.exactsciences.com/investor-relations/default.aspx |
HQ State/Province | Wisconsin |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Mid Cap/Growth |
Next Earnings Release | Feb. 21, 2025 (est.) |
Last Earnings Release | Nov. 05, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
URL | https://www.exactsciences.com |
Investor Relations URL | https://investor.exactsciences.com/investor-relations/default.aspx |
HQ State/Province | Wisconsin |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Mid Cap/Growth |
Next Earnings Release | Feb. 21, 2025 (est.) |
Last Earnings Release | Nov. 05, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |